polypharmacy in geraitric patients
Conditions
Interventions
Group 1: Observational Cohort who recieve treatment in Kreiskrankenhaus Wolgast from the 04.12.2023 until 30.06.2024. After the Patients discharge we will collect the following data from the doctor's
Sponsors
Institut für Pharmakologie der Univeritätsmedizin Greifswald
Eligibility
Sex/Gender
All
Age
70 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. understands the study purpose and design 2. contractually capable and provides signed informed consent form 3. admitted into specialized geriatric rehabilitation after an acute event
Exclusion criteria
Exclusion criteria: 1. admitted for acute surgical treatment 2. discharge before completion of the 2-week geriatric rehabilitation program
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in medication between admisson into the acute geriatric rehabilitation program and at dischcharge to determine the prevalence of polypharmacy and use of PIM. The medication plans will be collected from the doctor's letter. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Adverse events during hospital stay that are possibly linked to PIM use 2. renal function changes with eGFR using the CKD-EPI formula and other renal parameters (e.g. creatinine, potassium, sodium) 3. changes in liver function tests during hospital stay 4. changes in blood count during hospital stay | — |
Countries
Germany
Contacts
Public ContactStefan Engeli
Institut für Pharmakologie der Univeritätsmedizin Greifswald
Outcome results
None listed